163 related articles for article (PubMed ID: 1972359)
1. Clinical experience with Imdur in angina pectoris. A review.
Nyberg G
Eur J Clin Pharmacol; 1990; 38 Suppl 1():S65-8. PubMed ID: 1972359
[TBL] [Abstract][Full Text] [Related]
2. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
Gunasekara NS; Noble S
Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
[TBL] [Abstract][Full Text] [Related]
3. Abrupt withdrawal of isosorbide 5-mononitrate (Imdur) after long term treatment in stable angina pectoris. A preliminary report.
Rehnqvist N; Olsson G; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G; Uusitalo A; Keyriläinen O; Härkönen R
Drugs; 1987; 33 Suppl 4():118-21. PubMed ID: 2887419
[TBL] [Abstract][Full Text] [Related]
4. Long term efficacy of a controlled-release formulation of isosorbide 5-mononitrate (Imdur) in angina patients receiving beta-blockers.
Uusitalo A
Drugs; 1987; 33 Suppl 4():111-7. PubMed ID: 2887418
[TBL] [Abstract][Full Text] [Related]
5. Abrupt withdrawal of isosorbide-5-mononitrate in Durules (Imdur) after long term treatment in patients with stable angina pectoris.
Rehnqvist N; Olsson G; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G; Uusitalo A; Keyriläinen O; Reinikainen P
Eur Heart J; 1988 Dec; 9(12):1339-47. PubMed ID: 3147892
[TBL] [Abstract][Full Text] [Related]
6. Anti-anginal efficacy of a controlled-release formulation of isosorbide-5-mononitrate once daily in angina patients on chronic beta-blockade.
Uusitalo A; Keyriläinen O; Härkönen R; Rautio P; Rehnqvist N; Engvall J; Rosenqvist U; Nyberg G; Aberg A; Ulvenstam G
Acta Med Scand; 1988; 223(3):219-25. PubMed ID: 2895564
[TBL] [Abstract][Full Text] [Related]
7. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
Waller DG
J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
[TBL] [Abstract][Full Text] [Related]
8. Short and long-acting oral nitrates for stable angina pectoris.
Thadani U; Lipicky RJ
Cardiovasc Drugs Ther; 1994 Aug; 8(4):611-23. PubMed ID: 7848896
[TBL] [Abstract][Full Text] [Related]
9. Once- versus twice-daily administration of controlled-release isosorbide-5-mononitrate 60 mg in the treatment of stable angina pectoris. A randomized, double-blind, cross-over study. The Swedish Multicentre Group.
Nordlander R; Walter M
Eur Heart J; 1994 Jan; 15(1):108-13. PubMed ID: 8174569
[TBL] [Abstract][Full Text] [Related]
10. Experience of long term treatment and different dosage regimens of isosorbide 5-mononitrate.
Meffert M; Paeckelmann IM
Drugs; 1987; 33 Suppl 4():104-10. PubMed ID: 3622314
[TBL] [Abstract][Full Text] [Related]
11. Long-term therapeutic efficacy with once-daily isosorbide-5-mononitrate (Imdur).
Kendall MJ
J Clin Pharm Ther; 1990 Jun; 15(3):169-85. PubMed ID: 2195051
[No Abstract] [Full Text] [Related]
12. Acute and chronic effects of once-daily isosorbide-5-mononitrate on the exercise capacity of patients with angina pectoris treated with a beta-blocking drug.
Eteiba H; Hutton I; Foale RA; Akhras F; Jackson G; Prescott RJ; Hallam RJ; Quinn KJ
Br J Clin Pract; 1991; 45(3):185-8. PubMed ID: 1687200
[TBL] [Abstract][Full Text] [Related]
13. [Clinical significance of long-acting anti-anginal drugs in the treatment of cardiovascular diseases].
Watanabe H; Kato K
Kokyu To Junkan; 1990 Nov; 38(11):1081-9. PubMed ID: 1979885
[No Abstract] [Full Text] [Related]
14. Recent developments in the use of nitrates for treatment of angina pectoris.
Ankier SI; Warrington SJ; Sneddon JM
J Int Med Res; 1988; 16(4):249-56. PubMed ID: 3139481
[TBL] [Abstract][Full Text] [Related]
15. Anti-anginal and anti-ischemic efficacy of conventional and slow release formulations of isosorbide-5-mononitrate in angina pectoris.
Thadani U
Z Kardiol; 1985; 74 Suppl 4():21-4. PubMed ID: 4096067
[TBL] [Abstract][Full Text] [Related]
16. Nitrates: why and how should they be used today? Current status of the clinical usefulness of nitroglycerin, isosorbide dinitrate and isosorbide-5-mononitrate.
Silber S
Eur J Clin Pharmacol; 1990; 38 Suppl 1():S35-51. PubMed ID: 2113003
[TBL] [Abstract][Full Text] [Related]
17. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
Bonn R
Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of controlled-release isosorbide-5-mononitrate as adjunctive treatment to beta-blocking agents in patients with stable angina pectoris.
Svendsen JH; Aldershvile J; Abildgaard U; Amtorp O
J Cardiovasc Pharmacol; 1989 Sep; 14(3):358-63. PubMed ID: 2476613
[TBL] [Abstract][Full Text] [Related]
19. Absence of pre-dose rebound phenomena with once daily 5-ISMN in a controlled-release formulation.
Olsson G; Allgén J; Amtorp O; Nyberg G; Parker JO
Eur Heart J; 1992 Jun; 13(6):814-7. PubMed ID: 1623873
[TBL] [Abstract][Full Text] [Related]
20. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
